Esra A Akbay

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4382470/publications.pdf Version: 2024-02-01

331670 580821 3,753 27 21 25 h-index citations g-index papers 27 27 27 7820 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors. Cancer Discovery, 2013, 3, 1355-1363.	9.4	1,073
2	STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment. Cancer Research, 2016, 76, 999-1008.	0.9	451
3	Targeting Transcriptional Addictions in Small Cell Lung Cancer with a Covalent CDK7 Inhibitor. Cancer Cell, 2014, 26, 909-922.	16.8	376
4	Mutant IDH inhibits HNF-4Î $_{\pm}$ to block hepatocyte differentiation and promote biliary cancer. Nature, 2014, 513, 110-114.	27.8	367
5	Loss of Lkb1 and Pten Leads to Lung Squamous Cell Carcinoma with Elevated PD-L1 Expression. Cancer Cell, 2014, 25, 590-604.	16.8	332
6	Clinical implications of monitoring nivolumab immunokinetics in non–small cell lung cancer patients. JCl Insight, 2018, 3, .	5.0	156
7	Interleukin-17A Promotes Lung Tumor Progression through Neutrophil Attraction to Tumor Sites and Mediating Resistance to PD-1 Blockade. Journal of Thoracic Oncology, 2017, 12, 1268-1279.	1.1	152
8	Suppression of Myeloid Cell Arginase Activity leads to Therapeutic Response in a NSCLC Mouse Model by Activating Anti-Tumor Immunity. , 2019, 7, 32.		92
9	Lkb1 inactivation drives lung cancer lineage switching governed by Polycomb Repressive Complex 2. Nature Communications, 2017, 8, 14922.	12.8	80
10	D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice. Genes and Development, 2014, 28, 479-490.	5.9	70
11	Highly immunogenic cancer cells require activation of the WNT pathway for immunological escape. Science Immunology, 2021, 6, eabc6424.	11.9	64
12	Characterization of the Immune Landscape of EGFR-Mutant NSCLC Identifies CD73/Adenosine Pathway as a Potential Therapeutic Target. Journal of Thoracic Oncology, 2021, 16, 583-600.	1.1	62
13	Identification and characterization of an alternative cancer-derived PD-L1 splice variant. Cancer Immunology, Immunotherapy, 2019, 68, 407-420.	4.2	53
14	Pulsatile MEK Inhibition Improves Anti-tumor Immunity and T Cell Function in Murine Kras Mutant Lung Cancer. Cell Reports, 2019, 27, 806-819.e5.	6.4	51
15	EGFR inhibition triggers an adaptive response by co-opting antiviral signaling pathways in lung cancer. Nature Cancer, 2020, 1, 394-409.	13.2	51
16	Assessing Therapeutic Efficacy of MEK Inhibition in a KRASG12C-Driven Mouse Model of Lung Cancer. Clinical Cancer Research, 2018, 24, 4854-4864.	7.0	49
17	Image-guided radiotherapy platform using single nodule conditional lung cancer mouse models. Nature Communications, 2014, 5, 5870.	12.8	44
18	Cell-autonomous immune gene expression is repressed in pulmonary neuroendocrine cells and small cell lung cancer. Communications Biology, 2021, 4, 314.	4.4	44

ESRA A AKBAY

#	Article	IF	CITATIONS
19	Evasion of Innate Immunity Contributes to Small Cell Lung Cancer Progression and Metastasis. Cancer Research, 2021, 81, 1813-1826.	0.9	41
20	Dysfunctional telomeres trigger cellular senescence mediated by cyclic GMP-AMP synthase. Journal of Biological Chemistry, 2020, 295, 11144-11160.	3.4	32
21	Kinase Domain Activation of FGFR2 Yields High-Grade Lung Adenocarcinoma Sensitive to a Pan-FGFR Inhibitor in a Mouse Model of NSCLC. Cancer Research, 2014, 74, 4676-4684.	0.9	31
22	AXL targeting restores PD-1 blockade sensitivity of STK11/LKB1 mutant NSCLC through expansion of TCF1+ CD8 TÂcells. Cell Reports Medicine, 2022, 3, 100554.	6.5	29
23	Differential Roles of Telomere Attrition in Type I and II Endometrial Carcinogenesis. American Journal of Pathology, 2008, 173, 536-544.	3.8	25
24	Autochthonous murine models for the study of smoker and never-smoker associated lung cancers. Translational Lung Cancer Research, 2018, 7, 464-486.	2.8	11
25	The impact of the MYB-NFIB fusion proto-oncogene in vivo. Oncotarget, 2016, 7, 31681-31688.	1.8	11
26	Comprehensive targeting of resistance to inhibition of RTK signaling pathways by using glucocorticoids. Nature Communications, 2021, 12, 7014.	12.8	6
27	602â€AXL targeting with bemcentinb restores PD-1 blockade sensitivity of STK11/LKB1 mutant NSCLC through innate immune cell mediated expansion of TCF1+ CD8 T cells. , 2021, 9, A632-A632.		Ο